Unique ID issued by UMIN | UMIN000019873 |
---|---|
Receipt number | R000022963 |
Scientific Title | An observational study investigating the treatment satisfaction of atopic dermatitis patients who have switched to ointment (W/O emulsion) formulation of Very Strong Class topical corticosteroids |
Date of disclosure of the study information | 2015/11/20 |
Last modified on | 2018/03/29 18:54:00 |
An observational study investigating the treatment satisfaction of atopic dermatitis patients who have switched to ointment (W/O emulsion) formulation of Very Strong Class topical corticosteroids
Ointment treatment satisfaction for atopic dermatitis patients
An observational study investigating the treatment satisfaction of atopic dermatitis patients who have switched to ointment (W/O emulsion) formulation of Very Strong Class topical corticosteroids
Ointment treatment satisfaction for atopic dermatitis patients
Japan |
atopic dermatitis
Dermatology |
Others
NO
To investigate atopic dermatitis patients' treatment satisfaction when their treatment is switched from Fatty Ointment to Ointment(W/O emulsion)formulations of Potency ClassII topical steroids(TCs).
Efficacy
Exploratory
Pragmatic
Phase IV
Treatment satisfaction measured by Treatment Satisfaction Questionnaire for Medication (TSQM-9)
-Treatment adherence measured by Morisky Medication Adherence Scale (MMAS-8-Item)
-Treatment effectiveness measured by Visual Analogue Scale (VAS) for itch and change in severity score measured by Severity Scoring of Atopic -Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI).
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) Female and male patients with a diagnosis of atopic dermatitis who are treated with Fatty Ointment Potency Class II(Very strong class) TCs
2) Patients who are scheduled to change the formulation of the Potency Class II TC from Fatty Ointment to Ointment (Water in Oil; W/O emulsion) as per investigator's routine treatment practice
3) Patients who are aged over 20
4) Patients who are able to understand and sign a written informed consent
1) Patients with any contraindication to TCs
2) Patients who are pregnant or breastfeeding
3) Patients who are regarded as ineligible by the investigator
60
1st name | |
Middle name | |
Last name | Keiichi Yamanaka |
Mie University
Graduate school of medicine, Department of dermatology
2-174 Edobashi, Tsu-shi, Mie Prefecture 514-8507 Japan
059-232-1111
yamake@clin.medic.mie-u.ac.jp
1st name | |
Middle name | |
Last name | Keiichi Yamanaka |
Mie University
Department of dermatology, Graduate school of medicine.
2-174 Edobashi, Tsu-shi, Mie Prefecture 514-8507 Japan
059-232-1111
yamake@clin.medic.mie-u.ac.jp
Mie University Hospital
Bayer Yakuhin, Ltd.
Profit organization
NO
三重大学医学部附属病院(三重県)
2015 | Year | 11 | Month | 20 | Day |
Published
Completed
2015 | Year | 11 | Month | 13 | Day |
2015 | Year | 11 | Month | 30 | Day |
2016 | Year | 11 | Month | 17 | Day |
2017 | Year | 01 | Month | 17 | Day |
2017 | Year | 06 | Month | 23 | Day |
-Treatment satisfaction measured by Treatment Satisfaction Questionnaire for Medication (TSQM-9)
-Treatment adherence measured by Morisky Medication Adherence Scale (MMAS-8-Item)
-Treatment effectiveness measured by Visual Analogue Scale (VAS) for itch and change in severity score measured by Severity Scoring of Atopic -Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI).
2015 | Year | 11 | Month | 20 | Day |
2018 | Year | 03 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022963